2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now

Bristol Myers Squibb and Pfizer offer above-average dividend yields—BMY ~3.76% (raised 1.6% to $0.63/qtr) and PFE ~6.04% (raised 2.3% last year to $0.43/qtr). Dividend safety looks stronger for BMY with an estimated FCF payout ratio ~45% (vs. PFE ~89%), though Pfizer’s higher yield comes with a narrower margin of safety amid legacy-drug declines. Operating performance cited shows BMY’s legacy portfolio down 4% YoY in Q2 ($5.4B) while its growth portfolio rose 15% to $7.6B; Pfizer saw Comirnaty and Paxlovid sales fall 34% and 95% YoY, offset by 18% operational growth in launched/acquired products and oncology gains (e.g., Padcev +27%, Lorbrena +41%).

Analysis

This is less about dividend yield and more about balance-sheet optionality. Bristol Myers can keep paying while still funding the revenue-replacement effort; Pfizer’s payout leaves far less room for a misstep, so the equity behaves more like a leveraged income instrument than a true defensive compounder. That distinction matters because markets usually grant a higher multiple to companies that can self-fund both the dividend and the next leg of growth.

In the next 1-3 quarters, the key catalyst is not absolute sales growth but whether the replacement portfolio can outpace legacy decay with enough consistency to de-risk capital returns. If BMY shows another clean print of growth-portfolio expansion, it can rerate on lower perceived payout risk even before the patent overhang is fully gone. PFE needs a visible FCF inflection from cost cuts and launches; without it, the stock is vulnerable to yield-chasing exiting when the market stops treating the dividend as a substitute for growth.

Contrarian view: the market may be underestimating how much of PFE’s appeal is already “duration risk” dressed up as income. A high yield is only attractive until investors question whether it is being paid out of a shrinking margin of safety. Conversely, BMY may deserve more credit as a self-help story with room for buybacks and deleveraging; the main falsifier is a slowdown in the growth portfolio or a step-up in cash demands that pushes payout coverage materially above current levels.

Key Decisions for Investors

• Long BMY / short PFE for 3-6 months as a relative-value income trade; thesis is safer FCF coverage and better earnings-quality rerating, with upside if healthcare rotates toward balance-sheet safety. Falsify if PFE’s FCF coverage improves decisively or BMY’s growth portfolio decelerates.
• If already long PFE for yield, trim and reallocate part of the book into BMY rather than adding outright exposure to the higher yield; the risk/reward favors the lower payout ratio and stronger capital-return flexibility.
• Use JNJ as the quality benchmark, not the target: if you want defensive healthcare exposure with less execution risk, BMY is the better upside/safety compromise, while PFE remains the income-yield-only name.
• Set a watch item on PFE next earnings: any guidance implying payout ratios stay near current levels for another 2-3 quarters should be treated as a negative catalyst for the stock multiple, even if the dividend itself remains intact.